Cartesian Therapeutics
RNAC
65 hedge funds and large institutions have $178M invested in Cartesian Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
23% more capital invested
Capital invested by funds: $144M → $178M (+$33.3M)
14% more funds holding
Funds holding: 57 → 65 (+8)
0.08% more ownership
Funds ownership: 1.62% → 1.7% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.72M |
| 2 |
Man Group
London,
United Kingdom
|
+$2M |
| 3 |
AG
Artal Group
Luxembourg
|
+$824K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$804K |
| 5 |
PVI
Pura Vida Investments
New York
|
+$779K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.01M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.24M |
| 3 |
VEA
Virtus ETF Advisers
New York
|
-$378K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$335K |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$259K |
RNAC Hedge Fund Activity: Q3 2018 in Review
65 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2018, worth a combined $178M — up 23% from $144M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RNAC positions and 4 closed out — a net gain of 8 holders — while 27 added to existing stakes and 15 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $2.72M. The largest seller was OrbiMed, cutting an estimated $2.01M.
- 65 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2018, up from 57 in Q2 2018.
- Funds reported $178M of Cartesian Therapeutics stock for Q3 2018, up 23% quarter-over-quarter.
- 12 funds opened new Cartesian Therapeutics positions in Q3 2018 and 4 closed out, a net change of +8 holders.
- The largest Cartesian Therapeutics buyer in Q3 2018 was Kennedy Capital Management, an estimated $2.72M added.
- The largest Cartesian Therapeutics seller in Q3 2018 was OrbiMed, an estimated $2.01M sold.
Based on aggregated 13F filings for Q3 2018.